SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Trump Says Anthropic No Longer Seen as National Security Threat 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
Thermo Fisher Scientific Inc., a leading U.S.-based medical equipment manufacturer, is reportedly close to finalizing an all-cash acquisition of clinical trial data management company Clario in a deal valued at around $10 billion, according to the Financial Times. While Reuters has not yet confirmed the report, sources suggest the announcement could come as early as Wednesday, provided no last-minute complications arise.
If completed, this would mark Thermo Fisher’s largest acquisition since its $17.4 billion purchase of contract research organization PPD in 2021. The deal underscores Thermo Fisher’s strategic push to expand its footprint in clinical research and digital health data management, sectors that have seen accelerated growth in recent years.
Clario, established in 2021 through the merger of health tech companies ERT and Bioclinica, provides advanced software solutions that help pharmaceutical companies manage and analyze clinical trial data efficiently. The company’s investors include private equity firms Nordic Capital and Astorg. Clario’s technology plays a vital role in streamlining drug development processes, making it an attractive acquisition target amid growing demand for AI-driven healthcare solutions.
Neither Thermo Fisher nor Clario has commented on the reported deal. However, the acquisition aligns with Thermo Fisher’s ongoing strategy of strengthening its portfolio through high-value takeovers. Earlier in 2024, the company announced plans to acquire Solventum’s purification and filtration business for approximately $4.1 billion, further enhancing its capabilities in life sciences and laboratory technologies.
With increasing global demand for laboratory tools and integrated data solutions, Thermo Fisher recently raised its annual profit and revenue forecasts, signaling confidence in its growth trajectory. The potential Clario acquisition would not only expand Thermo Fisher’s reach in clinical research but also reinforce its position as a global leader in healthcare innovation and biotechnology.
